Evaluation of pharmaceutical industry - Sponsored educational events attended by physicians in Pakistan

Journal of Medical Marketing

Volumn 12, Issue 1, 2012, Pages 22-29

  Masood, Imran ^a   Mohamed Ibrahim, Mohamed Izham ^b   Ahmad Hassali, Mohamed Azmi ^a   Ahmad, Mahmood ^c   Mansfield, Peter R ^d  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b QATAR UNIVERSITY   (Qatar)

^c THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

CME; Code of conduct; Drug promotion; Pharmaceutical industry; Pharmaceutical marketing

Indexed keywords

EID: 84858191424     PISSN: 17457904     EISSN: 17457912     Source Type: Journal    
DOI: 10.1177/1745790411435373     Document Type: Article

References (36)

1. Steinbrook R. Financial support of continuing medical education. JAMA 2008; 299(9): 1060-1062. (Pubitemid 351347064)
2. Holmer AF. Industry strongly supports continuing medical education. JAMA 2001; 285(15): 2012-2014. (Pubitemid 32366958)
3. Ramogi MO. Who else but pharma will fund medical education? BMJ 2008; 337: 709.
4. Medicine Australia. Educational event reports. Deakin ACT 2600, 2008.
5. Relman AS. Industry support of medical education. JAMA 2008; 300(9): 1071-1073.
6. Steinman MA and Baron RB. Is continuing medical education a drug-promotion tool?: YES. Can Fam Phys 2007; 53(10): 1650-1653.
7. Moynihan R. Is the relationship between pharma and medical education on the rocks? BMJ 2008; 337: 484-485.
8. Editorial. What's wrong with CME? CMAJ 2004; 170(6): 917.
9. Relman AS. Defending professional independence: ACCME's proposed new guidelines for commercial support of CME. JAMA 2003; 289(18): 2418-2420. (Pubitemid 37430176)
10. Donoghue GD. Pharmaceutical sponsorship, CME, and the prurient desires of registrants. JAMA 1991; 266(21): 2986.
11. Rohra DK, Gilani AH, Memon IK, et al. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharmaceut Sci 2006; 9(1): 50-59. (Pubitemid 43257577)
12. Masood I and Anwar M. Common promotional materials and medical representatives: Are they really useful for doctors? In: Pharmacy in New Era, 1st National Conference on Pharmaceutical Sciences, 2-4 March, 2007, Bahawalpur, Pakistan.
13. Rohra D, Bashir M, Khwaja U and Nazir M. Critical appraisal of apparently evidence-based written advertising in Pakistan. Pharm World Sci 2008; 30(3): 216-221. (Pubitemid 351550904)
14. Rohra DK, Jawaid A, Tauseef-ur-Rehman, Sukkurwala AQ, Palanpurwala AS and Gangwani R. Prescription of new drugs by general practitioners in Pakistan: An exploration into information sources, prescription influences and general attitudes. Pakistan J Med Res 2007; 46(1): 5-10.
15. IFPMA. IFPMA Code of Pharmaceutical Marketing Practices. Geneva: International Federation Pharmaceutical Manufacturers Association, 2007.
16. WHO. Ethical Criteria for Medicinal Drugs Promotion. Endorsed by the 33rd World Health Assembly. Geneva: World Health Organization, 1986.
17. Drug Control Organization. Drugs (Licensing, Registering And Advertising) Rules, Drug Act 1976. 1976; http://www.dcomoh. gov.pk/regulations/drugrules2. php. Accessed July 28, 2009.
18. Drug Control Organization. Schedule G, The Drugs (Licensing, Registering and advertising) Rules, 1976 SRO (Solicitor's Remuneration Order) 1362(1)/96, dated November 28, 1996. Islamabad: Ministry of Health, Government of Pakistan, 1996.
19. Radhakrishna RB. Tips for developing and testing questionnaires/ instruments. J Extension 2007; 45(1).
20. Alipour A, Ghaffari M, Jensen I, Shariati B and Vingard E. Reliability and validity study of Persian modified version of MUSIC (musculoskeletal intervention center)-Norrtalje questionnaire. BMC Musculoskel Dis 2007; 8(1): 88.
21. Stat Soft. Reliability and item analysis. In: StatSoft Inc, ed. Electronic Statistics Textbook: Tulsa, OK: StatSoft; 2010: http://www.statsoft. com/textbook/reliability-and-item-analysis/
22. Smith R. Curbing the influence of the drug industry: A British view. PLoS Med 2005; 2(9): e241.
23. Jawaid S and Jafary M. Relationship between the medical profession and the Pharma industry: Need for greater scrutiny, transparency and accountability. Pak J Med Sci 2004; 20(4): 283-291. (Pubitemid 40030242)
24. Public Library of Science. Drug company-sponsored events for health professionals fail to disclose financial ties, analysis finds. Science Daily. November 3, 2009.
25. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA 2001; 285(15): 2009-2012. (Pubitemid 32366957)
26. Reist D and VandeCreek L. The pharmaceutical industry's use of gifts and educational events to influence prescription practices: Ethical dilemmas and implications for psychologists. Profession Psychol Res Practice 2004; 35(4): 329-335. (Pubitemid 39015886)
27. Dermksian G, Sarmiento A, Cleophas TJ, Cleophas RC, Madlon-Kay DJ and Relman AS. The pharmaceutical industry and continuing education. JAMA 2001; 286(3): 302-304.
28. Kmietowicz Z. Individual drug firms should stop paying for medical education. BMJ 2009; 338.
29. Tanne J. End pharma influence on CME, says AMA journal. BMJ 2006; 332(7555): 1410.
30. Robertson J, Moynihan R, Walkom E, Bero L and Henry D. Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med 2009; 6(11): e1000128.
31. Randall T. New guidelines examine drug firm, CME relations. JAMA 1991; 265(11): 1354.
32. Wollschlaeger B. Hooked: Ethics, the medical profession, and the pharmaceutical industry. JAMA 2008; 300(22): 2675-2676.
33. Mathew JL. Matters arising from industry link to education. BMJ 2008; 337.
34. Fletcher S. Pharma and CME: View from the US. BMJ 2008; 337.
35. Stelfox HT. Ethics and the pharmaceutical industry. JAMA 2006; 295(16): 1948-1949.
36. Shearer G, Duncan JM and Gadhia A. The Pharmaceutical Industry and Consumers - Key Factors Affecting Affordability of Prescription Drugs. Washington: Consumers Union, 2003.